Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
AbstractThe twin forces of payors seeking fair pricing and the rising costs of developing new medicines has driven a closer relationship between pharmaceutical companies and diagnostics companies, because stratified medicines, guided by companion diagnostics, offer better commercial, as well as clinical, outcomes. Stratified medicines have created clinical success and provided rapid product approvals, particularly in oncology, and indeed have changed the dynamic between drug and diagnostic developers. The commercial payback for such partnerships offered by stratified medicines has been less well articulated, but this has shifted as the benefits in risk management, pricing and value creation for all stakeholders become clearer. In this larger healthcare setting, stratified medicine provides both physicians and patients with greater insight on the disease and provides rationale for providers to understand cost-effectiveness of treatment. This article considers how the economic value of stratified medicine relationships can be recognized and translated into better outcomes for all healthcare stakeholders.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Blair, E.D.; Stratton, E.K.; Kaufmann, M. Aligning the Economic Value of Companion Diagnostics and Stratified Medicines. J. Pers. Med. 2012, 2, 257-266.
Blair ED, Stratton EK, Kaufmann M. Aligning the Economic Value of Companion Diagnostics and Stratified Medicines. Journal of Personalized Medicine. 2012; 2(4):257-266.Chicago/Turabian Style
Blair, Edward D.; Stratton, Elyse K.; Kaufmann, Martina. 2012. "Aligning the Economic Value of Companion Diagnostics and Stratified Medicines." J. Pers. Med. 2, no. 4: 257-266.